围术期靶向IV型胶原蛋白的Ac2-26纳米颗粒促进急性克罗恩病样结肠炎吻合口愈合:全身、口服和直肠给药途径的临床前研究
该临床前研究在急性克罗恩病样结肠炎小鼠模型中,评估了靶向IV型胶原蛋白的Ac2-26纳米颗粒((pc)-Col-IV-Ac2-26-NPs)经腹腔、口服和直肠三种途径给药对结肠吻合口愈合的影响。结果显示纳米颗粒以途径依赖方式富集于吻合口,增加胶原表达、减少促炎标志物并增加促消退标志物,其中直肠给药局部疗效最佳,口服最弱。结论提示该纳米颗粒可能成为高危克罗恩病手术患者的局部非免疫抑制疗法。
要点
- 靶向IV型胶原的Ac2-26纳米颗粒可选择性蓄积于结肠吻合口,且蓄积程度与给药途径相关。
- 直肠给药在改善术前疾病活动指数和术后内镜、组织学愈合评分方面效果最显著,口服给药效果最弱。
- 该纳米颗粒通过局部免疫调节促进吻合口愈合,不引起全身免疫抑制,可能适用于高危克罗恩病手术患者。
核心结论
- (pc)-Col-IV-Ac2-26-NPs通过靶向、途径依赖的免疫调节和组织修复促进克罗恩病结肠炎期间的吻合口愈合,直肠给药局部疗效最高。
- 这些发现支持其作为局部作用、非免疫抑制疗法用于接受肠道手术的高危克罗恩病患者的潜力。
研究设计与样本
- 临床前研究,使用雌性BALB/c小鼠(n=152)建立CD样结肠炎模型(2,4,6-三硝基苯磺酸诱导)并行远端结肠-结肠端端吻合。
- 小鼠随机接受(pc)-Col-IV-Ac2-26-NPs或乱序纳米颗粒,经腹腔、口服或直肠途径术前及术后每3.5天给药一次。
- 术后第3天和第7天评估围术期结局(体重减轻、疾病活动指数)、吻合口愈合评分(内镜、组织学)和免疫组化标志物。
主要发现
- 纳米颗粒以途径依赖方式选择性蓄积于吻合口,并与更高的胶原表达相关(P<0.0001)。
- 吻合口部位促炎标志物(核RelA;iNOS+ M1巨噬细胞)减少(所有P<0.0001),促消退标志物(ANXA1;Arg-1+ M2巨噬细胞)增加(所有P<0.0001)。
- 直肠给药效果最显著,对应术前DAI改善(P=0.03)、内镜愈合评分(POD3:P<0.0103;POD7:P<0.0077)和组织学愈合评分(POD3:P<0.0112;POD7:P<0.0170)改善。
- 腹腔给药产生相似结果,口服给药效果最弱。
临床怎么用
- 对于高危克罗恩病手术患者,局部直肠给予靶向IV型胶原的Ac2-26纳米颗粒可能促进吻合口愈合且不增加全身免疫抑制风险。
- 给药途径影响疗效,直肠途径可能优于口服,腹腔途径也可考虑,但需进一步临床验证。
局限性
- 本研究为临床前动物实验,结果不能直接外推至人类。
- 样本为雌性BALB/c小鼠,结论的性别和种属普适性有待验证。
- 仅评估了术后第3天和第7天的短期结局,长期疗效和安全性未报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This preclinical study investigates a novel targeted collagen type IV nanoparticle formulation, Ac2-26 coated with chitosan and pectin ((pc)-Col-IV-Ac2-26-NPs), to promote anastomotic healing in a model of acute Crohn's disease (CD) with distal colo-colonic anastomosis, using intraperitoneal, oral and rectal delivery to optimize therapeutic effects while minimizing systemic immunosuppression. SUMMARY BACKGROUND DATA: Surgery remains critical for CD-patients due to irreversible tissue damage, with anti-inflammatory therapies increasing the risk of postoperative complications like anastomotic leaks. METHOD: Female BALB/c mice (n=152) with CD-like colitis (2,4,6-Trinitrobenzenesulfonic acid) were randomized to receive (pc)-Col-IV-Ac2-26-NPs or scrambled NPs intraperitoneally, orally, or rectally every 3.5 days pre- and postoperatively, followed by distal end-to-end colo-colonic anastomosis. Perioperative outcomes (weight loss, disease activity index (DAI)), anastomotic healing scores (endoscopic, histologic), and immunohistochemical (IHC) markers were assessed on postoperative days (POD) 3 and 7. RESULTS: NPs accumulated selectively at the anastomosis in a route-dependent manner and associated with higher collagen expression (P<0.0001), reduced pro-inflammatory (nuclear RelA; iNOS+-M1 macrophages, all P<0.0001) and increased pro-resolving markers (ANXA1; Arg-1+-M2 Macrophages, all P<0.0001) at the anastomotic site. These effects were most pronounced with rectal delivery, corresponding with improved preoperative DAI (P=0.03) and both endoscopic (POD3:P<0.0103; POD7:P<0.0077) and histologic (POD3:P<0.0112; POD7:P<0.0170) healing scores. While intraperitoneal delivery produced similar outcomes, oral delivery showed the weakest effect. CONCLUSION: (pc)-Col-IV-Ac2-26-NPs promote anastomotic healing during CD-colitis through targeted, route-dependent immunomodulation and tissue repair, with rectal delivery showing the highest local efficacy. These findings support their potential as locally acting, non-immunosuppressive therapy for high-risk CD-patients undergoing intestinal surgery.
引用
- Cira K, Vieregge V, Pollak S, et al. Perioperative Collagen IV-Targeted Ac2-26 Nanoparticles Enhance Anastomotic Healing in Acute Crohn's Disease-Like Colitis: A Preclinical Study on Systemic, Oral, and Rectal Delivery Routes. Ann Surg. 2025. PMID: 40910845. doi:10.1097/SLA.0000000000006929
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。